Sunshine Biopharma Inc
NASDAQ:SBFM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sunshine Biopharma Inc
Revenue
Sunshine Biopharma Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sunshine Biopharma Inc
NASDAQ:SBFM
|
Revenue
$36.3m
|
CAGR 3-Years
103%
|
CAGR 5-Years
248%
|
CAGR 10-Years
167%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Revenue
CA$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Revenue
$283.1m
|
CAGR 3-Years
28%
|
CAGR 5-Years
41%
|
CAGR 10-Years
107%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Revenue
$7.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-7%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Revenue
CA$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sunshine Biopharma Inc
Glance View
Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Pointe-Claire, Quebec and currently employs 3 full-time employees. The company went IPO on 2008-08-15. In addition, the Company is engaged in the development and commercialization of science-based nutritional supplements. The Company’s drug development operations include SBFM-PL4 Anti-Coronavirus Treatment and Adva-27a Anticancer Drug. The firm is engaged in the development of its Anti-Coronavirus compound, SBFM-PL4. The company is advancing the development of two compounds in parallel with its SBFM-PL4. The Company’s drug development activities have focused on the development of a small molecule, Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells, including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells.
See Also
What is Sunshine Biopharma Inc's Revenue?
Revenue
36.3m
USD
Based on the financial report for Dec 31, 2025, Sunshine Biopharma Inc's Revenue amounts to 36.3m USD.
What is Sunshine Biopharma Inc's Revenue growth rate?
Revenue CAGR 10Y
167%
Over the last year, the Revenue growth was 4%. The average annual Revenue growth rates for Sunshine Biopharma Inc have been 103% over the past three years , 248% over the past five years , and 167% over the past ten years .
